

# Simone Claudiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8946055/publications.pdf>

Version: 2024-02-01

20  
papers

218  
citations

1307594

7  
h-index

1058476

14  
g-index

20  
all docs

20  
docs citations

20  
times ranked

353  
citing authors

#	ARTICLE	IF	CITATIONS
1	Is COVID-19 less severe in CML patients than in those with other haematological cancers?. British Journal of Haematology, 2022, 196, 471-472.	2.5	3
2	Assessment of quantitative polymerase chain reaction for <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?. British Journal of Haematology, 2022, 197, 52-62.	2.5	7
3	Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. Leukemia and Lymphoma, 2022, , 1-4.	1.3	1
4	Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. British Journal of Haematology, 2022, 197, .	2.5	13
5	Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. Cancers, 2021, 13, 4863.	3.7	1
6	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 193, 346-355.	2.5	18
7	Prolonged treatment-free remission in chronic myeloid leukemia patients with previous <i>BCR-ABL1</i> kinase domain mutations. Haematologica, 2020, 105, e225-e227.	3.5	7
8	Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia. Blood, 2020, 136, 20-20.	1.4	6
9	The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients. Leukemia and Lymphoma, 2019, 60, 3333-3334.	1.3	2
10	Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 <i>BCR-ABL1</i> . Leukemia and Lymphoma, 2019, 60, 3090-3091.	1.3	1
11	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica, 2019, 104, 2400-2409.	3.5	37
12	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica, 2019, 104, 2206-2214.	3.5	10
13	Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Annals of Hematology, 2019, 98, 321-330.	1.8	21
14	Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents. British Journal of Haematology, 2018, 182, 924-927.	2.5	6
15	The argument for using imatinib in CML. Hematology American Society of Hematology Education Program, 2018, 2018, 161-167.	2.5	34
16	34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia. Blood, 2018, 132, 5746-5746.	1.4	0
17	"Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets. Blood, 2018, 132, 1517-1517.	1.4	0
18	E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica, 2017, 102, e297-e299.	3.5	42

#	ARTICLE	IF	CITATIONS
19	Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia. <i>American Journal of Hematology</i> , 2016, 91, E480-E481.	4.1	7
20	Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy. <i>Blood</i> , 2016, 128, 1223-1223.	1.4	2